NCT07246525 Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission
| NCT ID | NCT07246525 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, San Francisco |
| Condition | Malaria |
| Study Type | INTERVENTIONAL |
| Enrollment | 4,800 participants |
| Start Date | 2026-09-22 |
| Primary Completion | 2029-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 4,800 participants in total. It began in 2026-09-22 with a primary completion date of 2029-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden. Given that school-aged children are the primary drivers of transmission, the study hypothesis is that IPTsc will reduce this infectious reservoir and thus the burden of malaria in persons of all ages in surrounding communities.
Eligibility Criteria
Inclusion Criteria: * Child currently attending the participating school. * Agreement of parent/guardian to provide informed consent. * Agreement of children aged 8-17 years to provide assent. Exclusion Criteria: * Missing school on three consecutive days of the school survey.
Contact & Investigator
Grant Dorsey, MD, PhD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07246525 clinical trial?
This trial is open to participants of all sexes, up to 17 Years, studying Malaria. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07246525 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07246525 currently recruiting?
Yes, NCT07246525 is actively recruiting participants. Contact the research team at grant.dorsey@ucsf.edu for enrollment information.
Where is the NCT07246525 trial being conducted?
This trial is being conducted at Kampala, Uganda.
Who is sponsoring the NCT07246525 clinical trial?
NCT07246525 is sponsored by University of California, San Francisco. The principal investigator is Grant Dorsey, MD, PhD at University of California, San Francisco. The trial plans to enroll 4,800 participants.